《大行報告》麥格理升創科(00669.HK)目標價至68元評級「跑贏大市」
麥格理發表研究報告指,創科(00669.HK)管理層在分析員會議上強調,公司在關稅陰霾下仍具有增長能力。管理層指,下半年會推出更多充電式產品,預料2020年地板護理業務將改善。同時,亦有信心未來三年毛利率每年可增長50點子。
該行預計,創科新高端產品增長強勁,不單可持續提高毛利率,亦可留下更多空間作營運支出投資。麥格理將創科2019年至2020年每股基本盈利預測調低3%至5%,至34.5美仙、39.5美仙及46.5美仙,以反映營運開支增加及地板護理銷售下跌。但將目標價由66元升至68元,重申評級「跑贏大市」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.